MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Balance Sheets Overview

Current Ratio
506.74%
Quick Ratio
506.74%
Cash Ratio
475.14%
Debt to Asset Ratio
134.35%
Unit: Thousand (K) dollars
Assets Breakdown
    • Cash and cash equivalents
    • Other non-current assets
    • Operating right-of-use asset
    • Other receivables
Liabilities Breakdown
    • Accumulated deficit
    • Additional paid-in-capital
    • Long-term debt, net
    • Others
Balance Sheets
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Cash and cash equivalents
133,344
161,657
124,220
153,088
Accounts receivable-Nonrelated Party
-
-
0
110
Other receivables
132
186
177
727
Accounts receivable-Related Party
-
-
0
0
Prepaid expenses and other current assets
8,736
9,498
8,435
7,498
Total current assets
142,212
171,341
132,832
161,423
Property and equipment, net
2,686
3,196
3,733
4,306
Operating right-of-use asset
4,555
5,052
5,535
6,004
Other non-current assets
4,769
4,378
4,378
5,738
Total assets
154,222
183,967
146,478
177,471
Accounts payable
9,800
8,762
5,944
6,773
Accrued expenses
15,773
15,342
25,529
26,963
Current portion of operating lease liability
2,491
2,408
2,326
2,247
Total current liabilities
28,064
26,512
33,799
35,983
Long-term debt, net
176,285
174,994
100,559
99,917
Non-current portion of operating lease liability
2,850
3,496
4,127
4,741
Total liabilities
207,199
205,002
138,485
140,641
Common stock, 0.0001 par value 120,000,000 shares authorized as of june30, 2026 and december31, 2025 14,708,910 shares issued and outstanding as of june30, 2026 and 14,577,609 shares issued and outstanding as of december31, 2025
1
1
1
1
Additional paid-in-capital
263,300
258,592
254,179
250,182
Accumulated deficit
-316,278
-279,628
-246,187
-213,353
Total stockholders equity (deficit)
-52,977
-21,035
7,993
36,830
Total liabilities and stockholders equity (deficit)
154,222
183,967
146,478
177,471
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Cash and cashequivalents$133,344K (-28.53%↓ Y/Y)Prepaid expenses andother current assets$8,736K (35.86%↑ Y/Y)Other receivables$132K (-81.92%↓ Y/Y)Total current assets$142,212K (-26.68%↓ Y/Y)Other non-currentassets$4,769K (-29.96%↓ Y/Y)Operating right-of-useasset$4,555K (-29.49%↓ Y/Y)Property and equipment,net$2,686K (-45.02%↓ Y/Y)Total assets$154,222K (-27.29%↓ Y/Y)Accumulated deficit-$316,278K (-77.59%↓ Y/Y)Total liabilities andstockholders equity...$154,222K (-27.29%↓ Y/Y)Total stockholdersequity (deficit)-$52,977K (-177.27%↓ Y/Y)Additionalpaid-in-capital$263,300K (6.75%↑ Y/Y)Common stock, 0.0001par value...$1K (0.00%↑ Y/Y)Total liabilities$207,199K (44.33%↑ Y/Y)Long-term debt, net$176,285K (77.57%↑ Y/Y)Total currentliabilities$28,064K (-27.93%↓ Y/Y)Non-current portion ofoperating lease liability$2,850K (-46.64%↓ Y/Y)Accrued expenses$15,773K (-44.61%↓ Y/Y)Accounts payable$9,800K (18.19%↑ Y/Y)Current portion ofoperating lease liability$2,491K (214.85%↑ Y/Y)

Inhibrx Biosciences, Inc. (INBX)

Inhibrx Biosciences, Inc. (INBX)